PDB: 13258 resultsInfo pagesStatus searchChemie searchBIRD

---

6P7W	Structure of the K. lactis CBF3 core - Ndc10 D1 complex Descriptor: Cep3, Ctf13, Ndc10, ... Authors: Lee, P.D, Wei, H, Tan, D, Harrison, S.C. Deposit date: 2019-06-06 Release date: 2019-09-18 Last modified: 2024-03-20 Method: ELECTRON MICROSCOPY (4.1 Å) Cite: Structure of the Centromere Binding Factor 3 Complex from Kluyveromyces lactis. J.Mol.Biol., 431, 2019
7Z8V	CAND1-SCF-SKP2 (SKP1deldel) CAND1 engaged SCF rocked Descriptor: Cullin-1, Cullin-associated NEDD8-dissociated protein 1, E3 ubiquitin-protein ligase RBX1, ... Authors: Baek, K, Schulman, B.A. Deposit date: 2022-03-18 Release date: 2023-04-19 Last modified: 2024-07-24 Method: ELECTRON MICROSCOPY (2.7 Å) Cite: Systemwide disassembly and assembly of SCF ubiquitin ligase complexes. Cell, 186, 2023
6P38	Crystal Structure Analysis of TAF1 Bromodomain Descriptor: 4-{[(3R)-4-cyclopentyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl]amino}-N-(1-methylpiperidin-4-yl)-3-[(propan-2-yl)oxy]benzamide, Transcription initiation factor TFIID subunit 1 Authors: Seo, H.-S, Dhe-Paganon, S. Deposit date: 2019-05-23 Release date: 2020-05-27 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (2.8 Å) Cite: Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. Acs Med.Chem.Lett., 10, 2019
6P7V	Structure of the K. lactis CBF3 core Descriptor: Cep3, Ctf13, Skp1 Authors: Lee, P.D, Wei, H, Tan, D, Harrison, S.C. Deposit date: 2019-06-06 Release date: 2019-09-11 Last modified: 2024-03-20 Method: ELECTRON MICROSCOPY (4 Å) Cite: Structure of the Centromere Binding Factor 3 Complex from Kluyveromyces lactis. J.Mol.Biol., 431, 2019
6FLE	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, SULFATE ION, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-01-25 Release date: 2019-02-06 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.48 Å) Cite: Crystal structure of ERK2 in complex with an adenosine derivative To be published
6PG6	WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamide Descriptor: CHLORIDE ION, N-{4-[4-(hydroxymethyl)-1H-imidazol-2-yl]butyl}acetamide, SULFATE ION, ... Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.68 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
4Y7R	Crystal structure of WDR5 in complex with MYC MbIIIb peptide Descriptor: 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, MYC MbIIIb peptide, ... Authors: Sun, Q, Phan, J, Olejniczak, E.T, Thomas, L.R, Fesik, S.W, Tansey, W.P. Deposit date: 2015-02-16 Release date: 2015-04-15 Last modified: 2023-09-27 Method: X-RAY DIFFRACTION (1.898 Å) Cite: Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. Mol.Cell, 58, 2015
6FJ0	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: 5'-deoxy-5'-(prop-2-yn-1-ylamino)adenosine, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-01-19 Release date: 2019-01-30 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.659 Å) Cite: Crystal structure of ERK2 in complex with an adenosine derivative To be published
6PGF	WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamide Descriptor: N-{4-[4-(hydroxymethyl)-1H-imidazol-2-yl]butyl}prop-2-enamide, SULFATE ION, WD repeat-containing protein 5 Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.54 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6FI6	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: (2~{R},3~{R},4~{S},5~{R})-2-(6-azanyl-8-diazanyl-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-01-17 Release date: 2019-01-30 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.65 Å) Cite: Crystal structure of ERK2 in complex with an adenosine derivative To be published
6PG3	WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanol Descriptor: (2-butyl-1H-imidazol-4-yl)methanol, WD repeat-containing protein 5 Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (2.04 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6PG5	WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate Descriptor: SULFATE ION, WD repeat-containing protein 5, benzyl {4-[5-(hydroxymethyl)-1H-imidazol-2-yl]butyl}carbamate Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.99 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6PGB	WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamide Descriptor: N-{4-[5-(hydroxymethyl)-1H-imidazol-2-yl]butyl}-2-phenylacetamide, SULFATE ION, WD repeat-containing protein 5 Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.73 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6FRP	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: 5'-azido-5'-deoxyadenosine, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-02-16 Release date: 2019-03-13 Last modified: 2024-05-15 Method: X-RAY DIFFRACTION (1.53 Å) Cite: None To be published
6P7X	Structure of the K. lactis CBF3 core - Ndc10 D1D2 complex Descriptor: Cep3, Ctf13, Ndc10, ... Authors: Lee, P.D, Wei, H, Tan, D, Harrison, S.C. Deposit date: 2019-06-06 Release date: 2019-09-18 Last modified: 2024-03-20 Method: ELECTRON MICROSCOPY (4.3 Å) Cite: Structure of the Centromere Binding Factor 3 Complex from Kluyveromyces lactis. J.Mol.Biol., 431, 2019
6FQ7	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: 4-[6-azanyl-9-[(2~{R},3~{R},4~{S},5~{R})-5-(azidomethyl)-3,4-bis(oxidanyl)oxolan-2-yl]purin-8-yl]sulfanylbutanoic acid, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-02-13 Release date: 2019-03-13 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.6 Å) Cite: None To be published
6PG8	WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanol Descriptor: CHLORIDE ION, SULFATE ION, WD repeat-containing protein 5, ... Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.67 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
2HFH	THE NMR STRUCTURES OF A WINGED HELIX PROTEIN: GENESIS, 20 STRUCTURES Descriptor: GENESIS Authors: Marsden, I, Jin, C, Liao, X. Deposit date: 1998-01-27 Release date: 1998-06-17 Last modified: 2024-05-29 Method: SOLUTION NMR Cite: Structural changes in the region directly adjacent to the DNA-binding helix highlight a possible mechanism to explain the observed changes in the sequence-specific binding of winged helix proteins. J.Mol.Biol., 278, 1998
6FMA	Crystal structure of ERK2 in complex with an adenosine derivative Descriptor: 3-[6-azanyl-9-[(2~{R},3~{R},4~{S},5~{R})-5-(azidomethyl)-3,4-bis(oxidanyl)oxolan-2-yl]purin-8-yl]sulfanylpropanoic acid, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... Authors: Gelin, M, Labesse, G. Deposit date: 2018-01-30 Release date: 2019-03-13 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.667 Å) Cite: None To be published
6PG4	WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanol Descriptor: (2-methyl-1H-imidazol-4-yl)methanol, SULFATE ION, WD repeat-containing protein 5 Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.6 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6PG9	WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamide Descriptor: N-{4-[4-(hydroxymethyl)-1H-imidazol-2-yl]butyl}benzamide, WD repeat-containing protein 5 Authors: Dennis, M.L, Peat, T.S. Deposit date: 2019-06-24 Release date: 2019-12-11 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.75 Å) Cite: Fragment screening for a protein-protein interaction inhibitor to WDR5. Struct Dyn., 6, 2019
6G97	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2 Descriptor: 6-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-2-(2-methoxyethyl)-3~{H}-isoindol-1-one, Mitogen-activated protein kinase 1, SULFATE ION Authors: O'Reilly, M. Deposit date: 2018-04-10 Release date: 2018-05-30 Last modified: 2018-06-27 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J. Med. Chem., 61, 2018
6G9H	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2 Descriptor: Mitogen-activated protein kinase 1, SULFATE ION, ~{N}-~{tert}-butyl-2-[5-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxidanylidene-1~{H}-isoindol-2-yl]-~{N}-methyl-ethanamide Authors: O'Reilly, M. Deposit date: 2018-04-10 Release date: 2018-05-30 Last modified: 2018-06-27 Method: X-RAY DIFFRACTION (1.73 Å) Cite: Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J. Med. Chem., 61, 2018
6G9D	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2 Descriptor: Mitogen-activated protein kinase 1, SULFATE ION, ~{N}-~{tert}-butyl-2-[5-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxidanylidene-1~{H}-isoindol-2-yl]ethanamide Authors: O'Reilly, M. Deposit date: 2018-04-10 Release date: 2018-05-30 Last modified: 2018-06-27 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J. Med. Chem., 61, 2018
6G9M	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2 Descriptor: 2-[5-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxidanylidene-1~{H}-isoindol-2-yl]-~{N}-(2-phenylpropan-2-yl)ethanamide, Mitogen-activated protein kinase 1, SULFATE ION Authors: O'Reilly, M. Deposit date: 2018-04-11 Release date: 2018-05-30 Last modified: 2018-06-27 Method: X-RAY DIFFRACTION (1.86 Å) Cite: Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J. Med. Chem., 61, 2018

<346347348349350351352353354355356357358359360361>